C
Cheng Zhang
Researcher at Guangzhou Institutes of Biomedicine and Health
Publications - 19
Citations - 221
Cheng Zhang is an academic researcher from Guangzhou Institutes of Biomedicine and Health. The author has contributed to research in topics: Bromodomain & Chemistry. The author has an hindex of 6, co-authored 9 publications receiving 129 citations. Previous affiliations of Cheng Zhang include Jilin University.
Papers
More filters
Journal ArticleDOI
Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.
Qiuping Xiang,Chao Wang,Yan Zhang,Xiaoqian Xue,Ming Song,Cheng Zhang,Chenchang Li,Chun Wu,Kuai Li,Xiaoyan Hui,Yulai Zhou,Jeff B. Smaill,Adam V. Patterson,Donghai Wu,Ke Ding,Yong Xu +15 more
TL;DR: The identification, optimization and evaluation of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 inhibitors starting from fragment-based virtual screening (FBVS) and a cocrystal structure of the inhibitor (22e) in complex with CBP provides a solid structural basis for further optimization.
Journal ArticleDOI
Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC)
Zhang Maofeng,Zhang Maofeng,Yan Zhang,Yan Zhang,Ming Song,Xiaoqian Xue,Xiaoqian Xue,Junjian Wang,Chao Wang,Cheng Zhang,Cheng Zhang,Chenchang Li,Chenchang Li,Qiuping Xiang,Qiuping Xiang,Lingjiao Zou,Lingjiao Zou,Xishan Wu,Xishan Wu,Chun Wu,Baijun Dong,Wei Xue,Y. Zhou,Hongwu Chen,Donghai Wu,Ke Ding,Yong Xu +26 more
TL;DR: The design, optimization, and evaluation of benzo[ d]isoxazole-containing compounds as potent BET bromodomain inhibitors represent a new class of compounds for the development of potential therapeutics against CRPC.
Journal ArticleDOI
Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer
Yan Zhang,Xishan Wu,Xishan Wu,Xiaoqian Xue,Xiaoqian Xue,Chenchang Li,Junjian Wang,Rui Wang,Cheng Zhang,Cheng Zhang,Chao Wang,Chao Wang,Shi Yudan,Shi Yudan,Lingjiao Zou,Lingjiao Zou,Qiu Li,Qiu Li,Zenghong Huang,Xiaojuan Hao,Kerry M. Loomes,Donghai Wu,Hongwu Chen,Jinxin Xu,Yong Xu +24 more
TL;DR: The potent, selective, metabolically stable, and orally available RORγ inverse agonists represent a new class of compounds as potential therapeutics against prostate cancer.
Journal ArticleDOI
Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.
Lingjiao Zou,Qiuping Xiang,Qiuping Xiang,Xiaoqian Xue,Cheng Zhang,Cheng Zhang,Chenchang Li,Chao Wang,Chao Wang,Qiu Li,Qiu Li,Rui Wang,Shuang Wu,Shuang Wu,Yulai Zhou,Yan Zhang,Yan Zhang,Yong Xu +17 more
TL;DR: Y08197, a novel 1-(indolizin-3-yl) ethanone derivative, is identified as a selective inhibitor of CBP/EP300 bromodomain and explored its antitumor activity against prostate cancer cell lines in vitro.
Journal ArticleDOI
Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer
Xiaoqian Xue,Yan Zhang,Chao Wang,Zhang Maofeng,Qiuping Xiang,Junjian Wang,Anhui Wang,Chenchang Li,Cheng Zhang,Lingjiao Zou,Rui Wang,Shuang Wu,Yong-Zhi Lu,Hongwu Chen,Ke Ding,Guohui Li,Yong Xu +16 more
TL;DR: Compound (R)-12 is a promising lead compound for the development of a new class of therapeutics for the treatment of CRPC, and demonstrates reasonable anti-proliferation and colony formation inhibition effect in prostate cancer cell lines such as 22Rv1 and C4-2B.